Two of the main approaches I consider will be necessary are 1) disclosure necessities, possibly based on the concept of enableabiliy, and 2) expertise switch hubs. More on the difficulty of biologics and the present debate concerning data exclusivity for generic biologics later. I believe that a more moral definition of an important drugs is one that doesn’t embrace reference to cost. Medicines should be defined as essential based mostly purely on an evaluation of medical want (this is a closer approximation of UAEM’s working definition of an ‘essential medicine’). I imagine that for any medication deemed ‘essential’ on this basis, measures must be taken to make it reasonably priced.

Leave a Reply